PUBLISHER: The Business Research Company | PRODUCT CODE: 1671015
PUBLISHER: The Business Research Company | PRODUCT CODE: 1671015
Viral and non-viral vector manufacturing involves the production of viral and non-viral vectors, which are tools designed to deliver genetic material into cells. Viral vectors are employed in the treatment of human diseases and find applications in anticancer and gene therapies. On the other hand, non-viral vectors are utilized for various gene therapy applications, with a particular focus on vaccine development and the treatment of cancer.
The main types of viral and non-viral vectors in manufacturing are viral vectors and non-viral vectors. Viral vectors are commonly used in gene therapy and gene editing to introduce therapeutic genes or alter the expression of existing genes in living organisms. These vectors are applied in the treatment of various diseases, including cancer, genetic diseases, infectious diseases, cardiovascular diseases, and others. They play a crucial role in gene therapy, vaccinology, cell therapy, and other related fields.
The viral and non-viral vector manufacturing vectors market research report is one of a series of new reports from The Business Research Company that provides viral and non-viral vector manufacturing vectors market statistics, including viral and non-viral vector manufacturing vectors industry global market size, regional shares, competitors with a viral and non-viral vector manufacturing vectors market share, detailed viral and non-viral vector manufacturing vectors market segments, market trends and opportunities, and any further data you may need to thrive in the viral and non-viral vector manufacturing vectors industry. This viral and non-viral vector manufacturing vectors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The viral and non-viral vector manufacturing market size has grown rapidly in recent years. It will grow from $8.67 billion in 2024 to $10.3 billion in 2025 at a compound annual growth rate (CAGR) of 18.8%. The growth in the historic period can be attributed to the rising prevalence of genetic disorders, advancements in biotechnology, increasing investments in gene therapy research, growing awareness of personalized medicine, and regulatory support for gene therapy development
The viral and non-viral vector manufacturing market size is expected to see exponential growth in the next few years. It will grow to $22.06 billion in 2029 at a compound annual growth rate (CAGR) of 21.0%. The growth in the forecast period can be attributed to rising demand for gene therapies, expanding applications in rare disease treatment, increasing investments in biomanufacturing infrastructure, and growing adoption of precision medicine. Major trends in the forecast period include the development of next-generation viral vectors, increased use of CRISPR or cas9 technology in vector manufacturing, focus on scalable and cost-effective manufacturing processes, rising adoption of non-viral vectors, and advancements in cell and gene therapy manufacturing technologies.
The growth of the viral and non-viral vector manufacturing markets is anticipated to be fueled by the increasing prevalence of genetic disorders. Genetic disorders arise from deviations in the typical DNA sequence, and viral vectors play a crucial role in delivering therapeutic genes to target cells, addressing defective genes causing these disorders. Non-viral vectors are commonly employed in ex vivo gene therapy, modifying cells outside the body before reintroducing them into the patient. For example, as reported by Versus Arthritis in June 2023, the number of people with rheumatoid arthritis, psoriatic arthritis, and osteoarthritis is expected to rise, highlighting the escalating incidence of genetic disorders and thereby propelling the growth of viral and non-viral vector manufacturing markets.
The growth of the viral and non-viral vector manufacturing markets is expected to be driven by the increasing number of clinical trials. Clinical trials, essential for evaluating the safety and efficacy of medical interventions, rely on viral and non-viral vectors to deliver therapeutic genes and ensure vector quality throughout trial phases. According to data from ClinicalTrials.gov in December 2023, the number of registered clinical trials has risen, with an increase in both registration and completion figures, underlining the pivotal role of these vectors in supporting gene therapy clinical trials and contributing to market growth.
A prominent trend in the viral and non-viral vector manufacturing markets is technological advancements. Key companies are investing in advanced solutions to maintain their market position. For instance, in August 2022, Merck KGaA launched the VirusExpress 293 Adeno-Associated Virus (AAV) Production Platform, providing a comprehensive viral vector manufacturing package. This innovative platform enables biopharmaceutical companies to streamline process development, reducing time and costs associated with clinical manufacture, showcasing the significance of technological advancements in driving market growth.
Major companies in the viral and non-viral vector manufacturing market are actively pursuing partnerships to enhance profitability. Collaborative efforts involve biopharmaceutical companies, contract development and manufacturing organizations (CDMOs), research institutions, and technology providers working together to improve efficiency, safety, and scalability of non-viral vector development and production. For instance, in September 2023, NecstGen and ProteoNic BioSciences collaborated to launch ProteoNic's 2G UNic premium vector technology, contributing to improved lentiviral (LV) vector development and production efficiency, ultimately benefiting gene therapies and non-vector processes.
In March 2023, Sartorius, a Germany-based supplier of pharmaceutical and laboratory equipment, acquired Polyplus for around $2.59 billion. This acquisition is intended to enhance Sartorius's position in the gene therapy and viral vector production markets by broadening its cell and gene therapy capabilities. Polyplus is a France-based biotechnology company specializing in the production of both viral and non-viral vectors for gene therapy applications.
Major companies operating in the viral and non-viral vector manufacturing market include Novartis AG, Thermo Fisher Scientific Inc., Merck KGaA, FUJIFILM Holdings Corporation, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc., Lonza Group AG, WuXi AppTec Co Ltd., Catalent Inc., Sartorius AG, Charles River Laboratories Inc., Sarepta Therapeutics Inc., GenScript ProBio Co. Ltd., TAKARA BIO Inc., Oxford BioMedica plc, Beam Therapeutics Inc., Intellia Therapeutics Inc., MaxCyte Inc., Voyager Therapeutics Inc., Genethon, MeiraGTx Holdings plc, Evox Therapeutics Ltd., Entos Pharmaceuticals Inc., LogicBio Therapeutics Inc., bluebird bio Inc., 4D Molecular Therapeutics Inc., Precision NanoSystems Inc., GenSight Biologics S.A., Abeona Therapeutics Inc., Generation Bio Co.
North America was the largest region in the viral and non-viral vector manufacturing market in 2024. The regions covered in the viral and non-viral vector manufacturing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the viral and non-viral vector manufacturing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The viral and non-viral vector manufacturing market includes revenues earned by entities by providing adeno-associated viral vectors, lentiviral vectors, retroviral vectors, adenoviral vectors, particle-based vectors, and chemical-based vectors. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Viral And Non-Viral Vector Manufacturing Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on viral and non-viral vector manufacturing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for viral and non-viral vector manufacturing ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The viral and non-viral vector manufacturing market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.